Related Experiment Videos
Leukotriene receptor blockade in experimental heart failure
M Pfeifer1, F Muders, A Luchner
1Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum, Regensburg, Germany.
Research in Experimental Medicine. Zeitschrift Fur Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie
|January 1, 1997
Summary
Endogenous leukotrienes do not appear to contribute to vasoconstriction in experimental heart failure. Blocking leukotriene receptors in heart failure dogs increased vascular resistance, suggesting a potential vasodilator role for leukotrienes.
Area of Science:
- Cardiovascular Physiology
- Renal Physiology
- Pharmacology
Background:
- The role of endogenous leukotrienes in cardiovascular and renal function during heart failure remains unclear.
- Congestive heart failure (CHF) involves complex pathophysiological changes affecting multiple organ systems.
Purpose of the Study:
- To investigate the role of endogenous leukotrienes in cardiovascular control and renal function regulation in a canine model of CHF.
- To determine the effects of a leukotriene receptor antagonist (FPL55712) on hemodynamic, hormonal, and renal parameters in healthy and heart failure states.
Main Methods:
- Conscious dogs underwent right ventricular pacing to induce heart failure over 10 days.
- The leukotriene receptor antagonist FPL55712 was administered intravenously to assess its effects.
- Hemodynamic parameters (heart rate, systemic vascular resistance, cardiac output), plasma hormone levels (norepinephrine, renin, aldosterone), and renal function (renal plasma flow, glomerular filtration rate) were measured.
Main Results:
- In healthy dogs, FPL55712 minimally affected hemodynamics but significantly decreased plasma norepinephrine, renin, and aldosterone.
- In dogs with heart failure, FPL55712 increased systemic vascular resistance and decreased cardiac output.
- In heart failure, FPL55712 altered renal function, decreasing renal plasma flow and increasing glomerular filtration rate, renal vascular resistance, and filtration fraction, without changing plasma hormone levels.
Conclusions:
- There is no evidence that endogenous leukotrienes contribute to systemic vasoconstriction in experimental heart failure.
- The observed increase in vascular resistance upon leukotriene receptor blockade in heart failure suggests a potential endogenous vasodilator role for leukotrienes, warranting further investigation.